Teva ups dosage to $2.1bn as investors gulp down pharma bond
![TevaAlamy20Nov2019](https://assets.euromoneydigital.com/dims4/default/53bd216/2147483647/strip/true/crop/230x150+0+0/resize/840x548!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2F4f%2F53%2Fa553564b8a27c37c8b9a0182416d%2Fteva-alamy-230x150-nov20.jpg)
Teva, the Israeli-US pharmaceutical company, priced a $2.1bn bond package at the tighter end of the initial price thoughts this week. While it is yet to come to a settlement over its alleged involvement in the US opioid crisis, investors were happy to jump aboard a rare double-B issue yielding up to 7%.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: